Abstract | INTRODUCTION:
Retigabine (RTG) is now approved in Europe and the US for the adjunctive treatment of partial-onset seizures in adults with epilepsy. To support submissions to EU reimbursement authorities, we explored its efficacy and tolerability relative to selected antiepileptic drugs (AEDs). METHODS: A systematic review was conducted to identify placebo-controlled trials of RTG and selected AEDs approved for use in a similar position in the management pathway of partial epilepsy ( eslicarbazepine acetate [ESL], lacosamide [LCM], pregabalin [ PGB], tiagabine [TGB] and zonisamide [ZNS]). Using conventional and network meta-analyses as appropriate, we report efficacy and tolerability outcomes for each AED versus placebo and the performance of RTG relative to other AEDs. RESULTS: Twenty studies met the inclusion criteria: three each for RTG, ESL, LCM, TGB and ZNS; five for PGB. Comparisons comprised 1-5 studies per AED. In the network meta-analysis, RTG was not found to be different from the other AEDs for responder rate (maintenance period), seizure freedom (maintenance period and double-blind period), withdrawals due to adverse events, and incidences of ataxia, dizziness, fatigue and nausea. Differences between RTG and other AEDs were found for a few comparisons, which did not reveal any trends: RTG was associated with a lower responder rate than PGB during the double-blind period, higher withdrawal rate due to any reason than ESL and a higher incidence of somnolence than TGB. CONCLUSIONS: Findings suggest that the risk/benefit for RTG is similar to that for comparator AEDs. However, results should be interpreted in the context of the limitations of the analyses.
|
Authors | Marrissa Martyn-St James, Julie Glanville, Rachael McCool, Steve Duffy, James Cooper, Pierre Hugel, Peter W Lane |
Journal | Seizure
(Seizure)
Vol. 21
Issue 9
Pg. 665-78
(Nov 2012)
ISSN: 1532-2688 [Electronic] England |
PMID | 22902288
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Copyright | Copyright © 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. |
Chemical References |
- Anticonvulsants
- Carbamates
- Phenylenediamines
- ezogabine
|
Topics |
- Anticonvulsants
(administration & dosage, adverse effects)
- Carbamates
(administration & dosage, adverse effects)
- Disorders of Excessive Somnolence
(chemically induced, epidemiology)
- Epilepsies, Partial
(drug therapy, epidemiology, physiopathology)
- Humans
- Phenylenediamines
(administration & dosage, adverse effects)
- Randomized Controlled Trials as Topic
(methods)
- Treatment Outcome
|